Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, announces that it has concluded a successful end of Phase II meeting with the US Food and Drug Administration ('FDA') for its ultra short course allergy vaccine Pollinex Quattro Ragweed.
